Blinatumomab improves event-free survival in children with high-risk B-cell ALL

Blinatumomab is associated with significantly higher event-free survival among children with newly diagnosed high-risk B-cell acute lymphoblastic leukemia (ALL), according to a study published in the Sept. 17 issue of the New England Journal of Medicine.